Open label, dose escalation Phase I study of AZD2281
Study identifier:D0810C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, open-label, dose escalation study to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies
Medical condition
Advanced solid malignancies
Phase
Phase 1
Healthy volunteers
No
Study drug
KU-0059436 (AZD2281)(PARP inhibitor)
Sex
All
Actual Enrollment
18
Study type
Interventional
Age
20 Years - 74 Years
Date
Study Start Date: 01 Nov 2007
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Jun 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
James Carmichael
KuDOS/AstraZeneca
